Apr 15, 2026 | J&J Q1 Earnings Beat on Tremfya Growth; Revolution Medicines $2B Raise

J&J's Tremfya hits $1.6B in Q1 sales with 74% growth,answering the Stelara biosimilar cliff. Plus: Revolution Medicines prices a $2B offering, Beeline launches with $300M and five BMS immunology assets, and Travere wins the first FDA approval for FSGS.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Johnson &Johnson, Tremfya, Stelara, Revolution Medicines, Beeline Medicines, BristolMyers Squibb, Bain Capital, Travere Therapeutics, Filspari, sparsentan, FSGS,Daiichi Sankyo, Suntory, Oric Pharmaceuticals, rinzimetostat, Foundayo,orforglipron, Eli Lilly, Allogene, CAR-T, peptides, GLP-1, Q1 earnings, Lilly,AstraZeneca, J&J, GSK, Sanofi, BMS